To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
HepaRegeniX GmbH Secures Series B Financing to Advance First Drug Candidate to the Clinic
HepaRegeniX, a preclinical stage
company developing a novel therapy for the treatment of acute and chronic liver
diseases, has announced the closing of its Series B financing round in excess of
€11 Mio. with contribution from all its existing investors.
The proceeds will be used to advance the
first MKK4 inhibitor for the treatment of acute and chronic liver diseases to the
clinics later in 2020. MKK4 (Mitogen-Activated Protein (MAP) Kinase 4) is a key
regulator of liver regeneration and suppression of MKK4 unlocks the
regenerative capacity of hepatocytes even in severely diseased livers. Over the
last 2.5 years, HepaRegeniX focused on discovery of new and proprietary MKK4
inhibitors which led to the identification of several preclinical drug
candidates. Results from experimental, clinically relevant disease models
further validated the concept that MKK4-inhibition improves the regeneration
capacity of hepatocytes in affected organs and provided strong evidence for
successful clinical development.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
